StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for DRIO yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $5.58M | $22.36M | $17.13M | $12.12M |
Operating Income | $-7.31M | $-36.66M | $-28.09M | $-18.61M |
Net Income | $-8.25M | $-41.71M | $-32.68M | $-22.22M |
EPS (Diluted) | $1.25 | $10.12 | $9.05 | $0.33 |
Total Assets | $103.28M | $110.08M | $117.73M | $108.33M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $14.98M | $21.80M | $31.91M | $21.95M |
Free Cash Flow OCF − CapEx | $-6.06M | $-26.08M | $-20.17M | $-12.78M |
Shares Outstanding | 7.30M | 6.91M | 6.77M | 45.47M |
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $8.39 | $8.30 | -1.13% | 0.0M |
| 05-18 | $8.75 | $8.35 | -4.57% | 0.0M |
| 05-19 | $8.20 | $8.20 | -0.00% | 0.0M |
| 05-20 | $8.01 | $8.00 | -0.12% | 0.0M |
| 05-21 | $8.11 | $7.55 | -6.91% | 0.0M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.